Spots Global Cancer Trial Database for Histological Confirmation of Clinical Clearance of Actinic Keratoses Following Treatment With Ingenol Mebutate Gel, 0.05%
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Histological Confirmation of Clinical Clearance of Actinic Keratoses Following Treatment With Ingenol Mebutate Gel, 0.05%
Official Title: Histological Confirmation of Clinical Clearance of Actinic Keratoses Following Treatment With Ingenol Mebutate Gel, 0.05%
Study ID: NCT01892137
Conditions
Interventions
Study Description
Brief Summary: The main purpose of this trial is to demonstrate the predictive value of the clinical diagnosis of clearance of Actinic Keratoses after treatment with Ingenol Mebutate using histopathological examination as the standard.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Southderm Pty Ltd, Kogarah, New South Wales, Australia
Melanoma Institute Australia, north Sydney, New South Wales, Australia
The Skin Centre, Benowa, Queensland, Australia
South East Dermatology Centre, Carina Heights, Queensland, Australia
St John of God Dermatology, Subiaco, Western Australia, Australia
Burswood Dermatology, Victoria Park, Western Australia, Australia
Klinik für Dermatologie & Allergologie Klinikum Augsburg Süd, Augsburg, , Germany
Collegium Medicum Berlin GmbH, Berlin, , Germany
Medizinisches Zentrum Bonn Friedensplatz, Bonn, , Germany
Hautarztpraxis Prof. Dr. med. C. Termeer, Stuttgart, , Germany
Contact Details
Name: Martina Ulrich
Affiliation: Collegium Medicum Berlin GmbH, Germany
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
